~~<i id='E22047E354'><strike id='E22047E354'><tt id='E22047E354'><pre id='E22047E354'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：hotspot 2025-10-02 04:12:43 Page View：3816

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wegovy improves function in certain heart failure patients
Next article： Activists slam private health insurers over coverage restrictions

focus

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

0:58AlifeguardstandswatchalongthelakefrontaswildfiresmokecloudstheskylineonJune28,2023inChicago.Scot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

KristofferTripplaar/APSANDIEGO–AnexperimentalpillfromEliLillyledto14.7%weightlossonthehighestdoseina